Georgina Long, BSc, PhD, MBBS, FRACP, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600–mutant melanoma.
Georgina Long, BSc, PhD, MBBS, FRACP, co-medical director, Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, University of Sydney, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600–mutant melanoma.
The COMBI-i study evaluated the combination of spartalizumab, dabrafenib (Tafinlar), and trametinib (Mekinist), says Long. Findings from parts 1 and 2 of the phase 3 trial were presented during the 2020 ASCO Virtual Scientific Program and showed encouraging clinical activity and tolerability with the novel triplet.
When using a BRAF inhibitor in combination with a MEK inhibitor, patient biopsies often show an influx of T cells within the first week of treatment, Long explains.
Ultimately, this was the rationale behind the study, as the field wanted to determine whether the addition of immunotherapy would induce prolonged, durable responses in this patient population, Long concludes.